Elraglusib is under clinical development by Actuate Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Elraglusib’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Elraglusib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Elraglusib overview

9-ING41 is under development for the treatment of solid tumors including primary myelofibrosis, post-polycythemia vera myelofibrosis (PPV-MF), salivary gland cancer, adenoid cystic carcinoma (ACC), post-essential thrombocythemia myelofibrosis (Post-ET MF), metastatic pancreatic adenocarcinoma, neuroblastoma, treatment sensitive and treatment-resistant glioblastoma (GBM), other cancers including breast cancer, renal cancer, lung cancer, ovarian cancer, esophageal cancer and pancreatic cancer, refractory hematologic malignancies, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, central nervous system tumors, prostate cancer, myxofibrosarcoma, leiomyosarcoma, liposarcoma, ependymoma, angiosarcoma, synovial sarcoma, rhabdomyosarcoma, spindle cell sarcoma, osteosarcoma, Ewing sarcoma, melanoma, pancreatic ductal adenocarcinoma, adult T-cell leukemia and lymphoma. The drug candidate is administered through intravenous route. The drug candidate is a small molecule and acts by targeting Glycogen synthase kinase-3 beta (GSK-3beta). It was also under development for the treatment of Alzheimer's disease and bladder cancer.

Actuate Therapeutics overview

Actuate Therapeutics is a biopharmaceutical company. It focuses on the development of novel compounds for the treatment of cancer and inflammatory diseases. The company’s lead compound 9-ING-41 is under evaluation for anti-tumor activity in various vivo models to treat cancers. Actuate aims to develop anti-cancer compounds for the treatment of brain, lung, breast, and pancreatic cancers. It also conducts research for the development of compounds to treat inflammatory diseases leading to fibrosis and neurodegeneration. The company seeks to partner with academic and life science companies to license, acquire, or partner on the development of novel compounds for oncology. Actuate is headquartered in Fort Worth, Texas, the US.

Quick View Elraglusib LOA Data

Report Segments
  • Innovator
Drug Name
  • Elraglusib
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.